HOXA9 and acute myeloid leukemia: Previously, we systematically identified the prognostic value of HOXA family gene methylation in AML, and revealed HOXA9 hypomethylation is an epigenetic biomarker for predicting clinical outcomes and guiding treatment choice in AML (7).